{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"14"},{"groupId":"BG007","value":"14"},{"groupId":"BG008","value":"7"},{"groupId":"BG009","value":"31"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"5"},{"groupId":"BG012","value":"7"},{"groupId":"BG013","value":"91"},{"groupId":"BG014","value":"111"},{"groupId":"BG015","value":"315"}],"units":"Participants"}],"groups":[{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 50 mg sunvozertinib, followed by a 7-day washout period. Then, they received 50 mg sunvozertinib once daily continuously.","id":"BG000","title":"Part A Dose Escalation Cohort 1: Sunvozertinib 50 mg"},{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 100 mg sunvozertinib, followed by a 7-day washout period. Then, they received 100 mg sunvozertinib once daily continuously.","id":"BG001","title":"Part A Dose Escalation Cohort 2: Sunvozertinib 100 mg"},{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 200 mg sunvozertinib, followed by a 7-day washout period. Then, they received 200 mg sunvozertinib once daily continuously.","id":"BG002","title":"Part A Dose Escalation Cohort 3: Sunvozertinib 200 mg"},{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 300 mg sunvozertinib, followed by a 7-day washout period. Then, they received 300 mg sunvozertinib once daily continuously.","id":"BG003","title":"Part A Dose Escalation Cohort 4: Sunvozertinib 300 mg"},{"description":"Patients with EGFR or HER2 mutations, previously treated with at least one line of systemic therapy.\n\nPatients received a single dose of 400 mg sunvozertinib, followed by a 7-day washout period. Then, they received 400 mg sunvozertinib once daily continuously.","id":"BG004","title":"Part A Dose Escalation Cohort 5: Sunvozertinib 400 mg"},{"description":"Patients with EGFR or HER2 exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients received sunvozertinib 200 mg once daily dosing in the fasted state continuously.","id":"BG005","title":"Part A Dose Expansion Cohort 1: Sunvozertinib 200 mg, Dosing in the Fasted State"},{"description":"Patients with EGFR or HER2 exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients received sunvozertinib 300 mg once daily dosing in the fasted state continuously.","id":"BG006","title":"Part A Dose Expansion Cohort 2: Sunvozertinib 300 mg, Dosing in the Fasted State"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients received sunvozertinib 200 mg once daily dosing with a low-fat meal continuously.","id":"BG007","title":"Part A Dose Expansion Cohort 3: Sunvozertinib 200 mg; Dosing With a Low-fat Meal"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients received sunvozertinib 300 mg once daily dosing with a low-fat meal continuously.","id":"BG008","title":"Part A Dose Expansion Cohort 4: Sunvozertinib 300 mg; Dosing With a Low-fat Meal"},{"description":"Patients with EGFR exon20ins, treatment naïve. Patients received sunvozertinib 300 mg once daily dosing with a low-fat meal continuously.","id":"BG009","title":"Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal"},{"description":"Patients with EGFR exon20ins, were refractory to, relapsed from, or intolerant to previous amivantamab treatment.\n\nNo patient was enrolled into this cohort.","id":"BG010","title":"Part A Dose Expansion Cohort 6: Previously Treated With Amivantamab; Sunvozertinib 300 mg"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized at a 1:1 ratio to receive a single dose of sunvozertinib 300 mg under the High-Fat Meal condition, followed by a 7-day washout and crossed to receive a single dose of sunvozertinib 300 mg under the Fasted condition, followed by a 7-day washout. Then patients received sunvozertinib 300 mg once daily continuously.","id":"BG011","title":"Part A Food Effect Cohort 1: Sunvozertinib 300 mg; High-Fat Meal Condition First, Then Fasted"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized at a 1:1 ratio to receive a single dose of sunvozertinib 300 mg under the Fasted condition, followed by a 7-day washout and crossed to receive a single dose of sunvozertinib 300 mg under the High-Fat Meal condition, followed by a 7-day washout. Then patients received sunvozertinib 300 mg once daily continuously.","id":"BG012","title":"Part A Food Effect Cohort 2: Sunvozertinib 300 mg; Fasted Condition First, Then High-Fat Meal"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized to receive sunvozertinib 200 mg once daily continuously.","id":"BG013","title":"Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized to receive sunvozertinib 300 mg once daily continuously.","id":"BG014","title":"Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg"},{"description":"Total of all reporting groups","id":"BG015","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"38","upperLimit":"72","value":"48.0"},{"groupId":"BG001","lowerLimit":"48","upperLimit":"83","value":"62.0"},{"groupId":"BG002","lowerLimit":"55","upperLimit":"74","value":"57.0"},{"groupId":"BG003","lowerLimit":"57","upperLimit":"82","value":"64.0"},{"groupId":"BG004","lowerLimit":"48","upperLimit":"85","value":"63.5"},{"groupId":"BG005","lowerLimit":"41","upperLimit":"83","value":"61"},{"groupId":"BG006","lowerLimit":"41","upperLimit":"76","value":"62.5"},{"groupId":"BG007","lowerLimit":"34","upperLimit":"73","value":"60.5"},{"groupId":"BG008","lowerLimit":"38","upperLimit":"73","value":"64"},{"groupId":"BG009","lowerLimit":"37","upperLimit":"96","value":"61"},{"groupId":"BG011","lowerLimit":"39","upperLimit":"82","value":"44.0"},{"groupId":"BG012","lowerLimit":"55","upperLimit":"78","value":"65.0"},{"groupId":"BG013","lowerLimit":"35","upperLimit":"88","value":"62"},{"groupId":"BG014","lowerLimit":"37","upperLimit":"89","value":"64"},{"groupId":"BG015","lowerLimit":"34","upperLimit":"96","value":"62.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"13"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"4"},{"groupId":"BG012","value":"6"},{"groupId":"BG013","value":"61"},{"groupId":"BG014","value":"63"},{"groupId":"BG015","value":"186"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"5"},{"groupId":"BG009","value":"18"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"30"},{"groupId":"BG014","value":"48"},{"groupId":"BG015","value":"129"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"10"},{"groupId":"BG006","value":"9"},{"groupId":"BG007","value":"13"},{"groupId":"BG008","value":"7"},{"groupId":"BG009","value":"23"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"59"},{"groupId":"BG014","value":"65"},{"groupId":"BG015","value":"204"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"2"},{"groupId":"BG015","value":"3"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"5"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"4"},{"groupId":"BG012","value":"6"},{"groupId":"BG013","value":"30"},{"groupId":"BG014","value":"44"},{"groupId":"BG015","value":"103"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"0"},{"groupId":"BG013","value":"0"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"1"},{"groupId":"BG013","value":"2"},{"groupId":"BG014","value":"0"},{"groupId":"BG015","value":"5"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"No patient was enrolled in Part A dose expansion cohort 6 due to conflict with enrollment of Part B."}